Pharmaceuticals Headlines from PR Newswire

< Go Back

Debiopharm Diagnostics Portfolio Company Biocartis Ships its First Idylla Instrument
Global Animal Medication Industry
3SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China
ROX Medical presents positive data for CONTROL-HTN resistant hypertension trial
Improved risk identification will aid fertility preservation in young male cancer patients
Kaiser Foundation Health Plan, Inc. and Kaiser Foundation Hospitals Name Interim Chief Information Officer
PFF Submits Survey Data From More Than 1,100 Pulmonary Fibrosis Patients And Families To U.S. Food And Drug Administration For Upcoming Drug Development Meeting
Christy Noland to Lead Urology Advocacy and Communications for Astellas
Endo Delivers A Proposal To Acquire Auxilium Pharmaceuticals For $28.10 Per Share In Cash And Stock
Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
Aratana Therapeutics, Inc. Announces Proposed Public Offering
Veteran Genoptix and Gen-Probe Executive, Brian Hansen, joins Adaptive Biotechnologies as Chief Commercial Officer
Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine
FDA Approves MOVANTIK™ (naloxegol) Tablets For The Treatment Of Opioid-Induced Constipation In Adult Patients With Chronic Non-Cancer Pain
Global Medicines for Russia
The Rheumatoid Arthritis Drug Market Will Grow to $18.2 Billion in 2023, Driven by the Uptake of Oral Jak Inhibitors and Non TNF-alpha Biologics
Abbott Included In Top 10 Best Companies by Working Mother Magazine
DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial
CorMedix Amends and Restates Outstanding Securities to Remove Provisions Causing Derivative Liability Classification
Synereca Pharmaceuticals Announces Financing Led by Accele Venture Partners
Imprimis Pharmaceuticals to Present at Craig-Hallum Alpha Select Conference
"UNVEIL" Survey Reveals a Life Interrupted by Lupus
Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER
Mylan Commences Phase III Clinical Trials for its Generic Version of Advair Diskus® and Insulin Analog to Lantus®
EYLEA® (aflibercept) Injection Receives FDA Breakthrough Therapy Designation for Diabetic Retinopathy in Patients with Diabetic Macular Edema
Lilly and AstraZeneca announce alliance to co-develop potential treatment for Alzheimer's disease
Sphere Fluidics Selects Cambridge Consultants as Product Engineering Partner for Cyto-Mine™ Development
Physician Improves Upon His Proven & Patented Dry Eye Syndrome Formula with Dry Eye Relief® TG-1000
Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium
STEM-Pharma® to Attend the 5th Innovation Days and Emerging Market Access Conference in Paris
Bayer and Orion Initiate Phase III Trial of ODM-201 in Men with High-Risk Non-Metastatic Castration-Resistant Prostate Cancer
Pharnext and the Hereditary Neuropathy Foundation Collaborate to Increase Awareness of Charcot-Marie-Tooth Disease
Pivotal Therapeutics Grants Incentive Stock Options
Asthma Market to Reach 161.02 million Cases in 10MM by 2023
Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017
Quinolone Vigilance Foundation Supports Citizen Petition Requesting Another Black Box Warning for Levaquin, Cipro, Avelox
Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia® (Denosumab) In Postmenopausal Women With Osteoporosis
New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density
CaPtivate Pharmaceuticals Enters License Agreement With Immunotope
myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO
Ampio Pharmaceuticals Announces Webcast for Annual Shareholder Meeting
More than $55 billion in fines and settlements added by SCCE to its 2015 Corporate Scandal Calendar
First European Patients Enrolled in QT Vascular's ENDURE Trial
PDL BioPharma Completes Regular Quarterly Dividend Payment
Paracetamol (Acetaminophen) (CAS 103-90-2) Market Research Report 2014
Closed Drug Transfer Systems to 2020
Lupus Research Institute Launches NYC's First Lupus Trials Fair
Sysmex America, Inc. Renews LABSCO Distributorship
MedExpress Quotes Late Summer, Early Fall As Best Time to Receive Flu Shot

< Prev Next >
PR Newswire - United Business Media